Stemline Therapeutics, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersNew York, NY
US patents10
SAM.gov UEILCGFF8XA1EZ4
CAGE code4CJM1
Incorporated inDE
LEI529900EFNCIRC8Q7V234
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
10 US patents granted 2012–2025, 5 of them in the five years to SEP 2025.
Pharmaceuticals 10
- Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agentsUS 12,357,700 · granted JUL 15, 2025
- Cancer stem cell targeted cancer vaccinesUS 12,357,678 · granted JUL 15, 2025
- IL3Ralpha antibodies and uses thereofUS 12,187,802 · granted JAN 7, 2025
- Cancer stem cell targeted cancer vaccinesUS 11,672,847 · granted JUN 13, 2023
- IL3Ralpha antibody conjugates and uses thereofUS 10,906,979 · granted FEB 2, 2021
Newest 5 shown · Granted to Stemline Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Stemline Therapeutics, INC. | New York | NY | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.